<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03806426</url>
  </required_header>
  <id_info>
    <org_study_id>EPA-POL-04</org_study_id>
    <nct_id>NCT03806426</nct_id>
  </id_info>
  <brief_title>Effect of EPA-FFA on Polypectomy in Familial Adenomatous Polyposis</brief_title>
  <official_title>Randomised, Double-blind, Placebo-controlled Study of the Efficacy, Safety and Tolerability of EPA-FFA Gastro-resistant Capsules, in Patients With Familial Adenomatous Polyposis (FAP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>S.L.A. Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>S.L.A. Pharma AG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      2 Year randomised, double-blind, placebo-controlled, parallel group study to determine the
      safety and efficacy of EPA-FFA gastro resistant capsules in FAP.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this Phase III study is to determine whether Eicosapentaenoic acid-free fatty
      acid is a safe and well tolerated treatment in reducing the number of polypectomies FAP
      patients with an APC gene mutation have over a 2 year treatment period and to assess the
      effect that this has on clinical disease progression. Planned Sample Size This study will
      enrol 204 subjects (102 subjects per treatment group). Primary Objective is to determine the
      efficacy of EPA-FFA gastro-resistant capsules in patients with FAP in reducing polypectomy.

      Secondary objectives is to evaluate the clinical disease progression and the long-term safety
      and tolerability of EPA-FFA.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 5, 2018</start_date>
  <completion_date type="Anticipated">March 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Number of Polypectomies (polyps &gt; 5mm in the rectum) conducted during the 24 months study period</measure>
    <time_frame>24 months</time_frame>
    <description>Proctectomy is indicated when polyp burden is frequently high in the remaining rectum, if large highly dysplastic polyps occur, or if frank malignancy develops. Proctocolectomy also significantly reduces the cancer risk with the removal of the colon and rectum.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Polyp number at 24 months assessed by blinded review of video records</measure>
    <time_frame>24 months</time_frame>
    <description>Subsequent proctectomy is indicated when polyp burden is frequently high in the remaining rectum, if large highly dysplastic polyps occur, or if frank malignancy develops. Proctocolectomy also significantly reduces the cancer risk with the removal of the colon and rectum.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in score on the InSIGHT Polyposis Staging System (IPSS) at 24 months</measure>
    <time_frame>24 months</time_frame>
    <description>Classified stage on InSiGHT Polyposis Staging System (IPSS). The subjects FAP will be classified in accordance with the IPSS.
The IPSS classification will be verified by the Polyp Video Scoring committee</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">204</enrollment>
  <condition>Familial Adenomatous Polyposis</condition>
  <arm_group>
    <arm_group_label>Treatment Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eicosapentaenoic acid free fatty acid (EPA-FFA) 500mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Group B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 500mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eicosapentaenoic acid free fatty acid (EPA-FFA)</intervention_name>
    <description>500mg capsule, two 500mg capsules to be taken twice daily for 24 months</description>
    <arm_group_label>Treatment Group A</arm_group_label>
    <other_name>ALFA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>500mg capsule, two 500mg capsules to be taken twice daily for 24 months</description>
    <arm_group_label>Treatment Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Must give written informed consent.

          2. Male or female subjects, 18 to 65 years of age.

          3. Known diagnosis of FAP defined as those with a pathogenic APC mutation and have had a
             previous colectomy with ileo-rectal anastomosis.

          4. Subjects must have a preserved rectum.

          5. Classified stage 1-3 on InSiGHT Polyposis Staging System (IPSS).

          6. Subjects must show a willingness to abstain from regular use of non-steroidal
             anti-inflammatory medication for the trial. A cardioprotective dose of aspirin
             (75mg-100mg) will be permitted.

        Exclusion Criteria:

          1. In subjects with previous ileo-rectal anastomosis â‰¥ 20 polyps &gt; 5mm in the rectum.

          2. Subjects with an ileo-anal pouch.

          3. Subjects unwilling to have regular endoscopic examination.

          4. Subjects who are due to undergo gastro-intestinal surgery related to FAP.

          5. History of invasive carcinoma in the past 3 years.

          6. History of pelvic radiation.

          7. Known allergic reaction or intolerant to fish or fish oils.

          8. Known allergic reaction to excipients of IMP and placebo.

          9. Subjects who are pregnant or breast-feeding at screening.

         10. Subjects taking aspirin or other non-steroidal anti-inflammatory drugs on a regular
             basis other than low dose (75mg-100mg) cardioprotective dose.

         11. Subjects taking NSAIDs regularly in the 3 months prior to entry (other than low dose
             aspirin).

         12. Subjects who are taking other fish-oil supplements (e.g. cod liver oil) who are
             unwilling to stop them for the duration of the study. Subjects previously taking fish
             oil must have a washout period of 2 months prior to study enrolment.

         13. Subjects who are taking warfarin or other anticoagulants.

         14. Experimental agents must have been discontinued at least 8 weeks prior to screening
             for a period equivalent to 5 half-lives of the agent (whichever is longer).

         15. Subjects suffering from known disorders of clotting and blood coagulation.

         16. Subjects who have significant abnormalities on their screening blood tests.

         17. Subjects with gastrointestinal malabsorptive disease.

         18. Subjects with uncontrolled hypercholesterolaemia.

         19. Subjects who are deemed mentally incompetent, or have a history of anorexia nervosa or
             bulimia.

         20. Subjects who will be unavailable for the duration of the trial, deemed unable to
             comply with the requirements of the study protocol, likely to be noncompliant with the
             protocol, or who are felt to be unsuitable by the Investigator for any other reason.

         21. Women of childbearing potential, defined as all women physiologically capable of
             becoming pregnant, unless surgically sterile must use effective contraception (either
             combined estrogen and progestogen containing hormonal contraception associated with
             inhibition of ovulation [oral, intravaginal, transdermal], progestogen only hormonal
             contraception associated with inhibition of ovulation [oral, injectable, implantable],
             intrauterine device [IUD], intrauterine hormone-releasing system [IUS], vasectomised
             partner, sexual abstinence (only considered an acceptable method of contraception when
             it is in line with the subjects' usual and preferred lifestyle), combination of male
             condom with either cap, diaphragm or sponge with spermicide [double barrier methods]),
             and willing and able to continue contraception for 1 month after the last
             administration of IMP. Women using oral contraception must have started using it at
             least 2 months prior to screening. Women are not considered to be of childbearing
             potential if they have had 12 months of natural (spontaneous) amenorrhea with an
             appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or
             six months of spontaneous amenorrhea with serum FSH levels that have been confirmed to
             be in the &quot;postmenopausal range&quot;. Or have had a surgical bilateral oophorectomy (with
             or without hysterectomy) or bilateral tubal ligation at least six weeks before the
             screening visit. In case of oophorectomy alone, the reproductive status of the woman
             should have been confirmed by follow up hormone level assessment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luigi Ricciardiello, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Associate Professor of Gastroenterology, University of Bologna</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Justin Slagel, CEO</last_name>
    <phone>+44 1923 681001</phone>
    <email>info@slapharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Brno</name>
      <address>
        <city>Brno</city>
        <zip>625 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Milan Dastych, RN</last_name>
      <email>Dastych.milan@fnbrno.cz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Hradec Kralove</name>
      <address>
        <city>Hradec KrÃ¡lovÃ©</city>
        <zip>500 05</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Veronika Knoblochova</last_name>
      <email>veronika.knoblochova@fnhk.cz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mediendo Ltd</name>
      <address>
        <city>Praha</city>
        <zip>186 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stepan Suchanek, Dr</last_name>
      <email>stepan.suchanek@uvn.cz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <zip>93000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospices Civils de Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Saint-Antoine Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rambam Healthcare Campus</name>
      <address>
        <city>Haifa</city>
        <state>Bat Galim</state>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maza Itai, Dr</last_name>
      <phone>+972-4-777-1912</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Soroka Medical Center</name>
      <address>
        <city>Be'er Sheva</city>
        <zip>84101</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro di Riferimento Oncologico di aviano</name>
      <address>
        <city>Aviano</city>
        <zip>33081</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Bologna and St.Orsola-Malpighi Hospital</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>IRCCS de Bellis</name>
      <address>
        <city>Castellana Grotte</city>
        <zip>70013</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istituto nazionale dei Tumori</name>
      <address>
        <city>Milan</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo di Oncologia</name>
      <address>
        <city>Milan</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori Fondazione G.Pascale</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giovanni Battista Rossi</last_name>
      <email>g.rossi@istitutotumori.na.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oncologic Institute of Rome</name>
      <address>
        <city>Roma</city>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lupe Sanchez Mete</last_name>
      <email>lupe.sanchez@ifo.gov.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Clinico humanitas</name>
      <address>
        <city>Rozzano</city>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale Casa Sollievo della Sofferenza</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <zip>71013</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marianna Nardella</last_name>
      <email>mariannardella@alice.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Molinette</name>
      <address>
        <city>Turin</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Academic Medical Centre</name>
      <address>
        <city>Amsterdam</city>
        <zip>1100 DE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victorine Roos</last_name>
      <email>v.h.roos@amc.uva.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Radboud University Medical Center</name>
      <address>
        <city>Nimega</city>
        <zip>6525</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicoline Hoogerbrugge</last_name>
      <email>nicoline.hoogerbrugge@radboudumc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Alicante</name>
      <address>
        <city>Alicante</city>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebeca Moreira</last_name>
      <email>RMOREIRA@clinic.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complexo Hospitalario de Ourense</name>
      <address>
        <city>Ourense</city>
        <zip>32003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Complexo Hospitalario Universitario de Pontevedra</name>
      <address>
        <city>Pontevedra</city>
        <zip>36071</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Alvaro Cunqueiro</name>
      <address>
        <city>Pontevedra</city>
        <zip>36312</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Canarias</name>
      <address>
        <city>Santa Cruz De Tenerife</city>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario Lozana Blesa</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>France</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>January 9, 2019</study_first_submitted>
  <study_first_submitted_qc>January 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 16, 2019</study_first_posted>
  <last_update_submitted>June 14, 2019</last_update_submitted>
  <last_update_submitted_qc>June 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Eicosapentaenoic Acid</keyword>
  <keyword>EPA</keyword>
  <keyword>EPA 99%</keyword>
  <keyword>Fatty Acid</keyword>
  <keyword>omega-3</keyword>
  <keyword>polyp</keyword>
  <keyword>Familial Adenomatous Polyposis</keyword>
  <keyword>FAP</keyword>
  <keyword>IRA (Ileo-rectal anastomosis)</keyword>
  <keyword>PUFA (polyunsaturated fatty acid)</keyword>
  <keyword>Endoscopy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
    <mesh_term>Adenomatous Polyposis Coli</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

